TIER 1 · ACTIVE PURSUIT · PHARMA & LIFE SCIENCES R&D
Audit infrastructure / for drug development AI.
FDA asks one question at every GxP inspection now: "Show me how this was generated." For AI-augmented drug discovery, clinical trials, manufacturing, and pharmacovigilance, the answer is documented audit evidence. Yolo's audit chain is that evidence — for every AI-influenced decision, every model version, every data input, every reviewer.
August 2, 2026: EU AI Act enforcement for medical devices and IVDs classified as high-risk. FDA-EMA Good AI Practice Principles (January 14, 2026) — first formal US-EU co-publication on AI in drug development.
REGULATORY OBLIGATIONS
FDA-EMA Joint Good AI Practice Principles
Active · US + EU
January 14, 2026 — 10 principles
First formal US-EU co-publication on AI in drug development. Requires data provenance, transparency, bias control, traceable documentation, and risk-based credibility assessment for all AI used in regulated drug development.
FDA Purolea Cosmetics warning letter (April 2, 2026)
Active enforcement · 2026
AI overreliance / human oversight (cGMP)
"Show me how this was generated, and who reviewed it" is now the inspection question. The first FDA letter to cite AI overreliance / lack of human oversight in a regulated decision as a cGMP deficiency (it did not allege missing audit trails). Sponsors without a defensible record of how AI decisions were made and reviewed face inspection exposure.
EU AI Act
Aug 2 2026 / Dec 2 2027*
Article 12 — record-keeping (Annex III high-risk for medical devices and IVDs)
Medical devices and IVDs using AI are Annex III high-risk by default. Requires structured, exportable, defensible logs. Penalty: 3% of global annual turnover or €15M under Article 99(4).
FDA CSA + 21 CFR Part 11
Active · US
Computer Software Assurance (Sept 2025, updated Feb 2026) + Electronic records
Risk-based CSA replacing prescriptive CSV. 21 CFR Part 11 requires electronic records integrity and audit trail for GxP systems. AI decisions generating regulatory submission data must be traceable to model version and inputs.
GAMP 5 + ICH Q7-Q11 + ALCOA+
Active · global
GxP validation framework + international quality standards + data integrity
GAMP 5 Second Edition validation framework, ICH Q7–Q11 international pharmaceutical quality standards, cGMP/GLP/GCP/GVP good practice frameworks, and ALCOA+ data integrity tenets all require attributable, legible, contemporaneous, original, and accurate AI decision records.
EMA Reflection Paper on AI + MHRA AI Strategy
Active · EU + UK
Sept 2024 basis for EMA AI guidelines + April 2024 five-pillar framework
EMA September 2024 reflection paper sets the basis for forthcoming AI guidelines for medicines. MHRA April 2024 five-pillar AI strategy applies to AI-enabled medical devices in UK market. Both converge on traceable audit evidence.
* EU AI Act Annex III enforcement date: August 2, 2026 (legally operative). EU Digital Omnibus provisional agreement (May 7, 2026) proposes extending to December 2, 2027 — not yet formally enacted. Prepare for the earlier date.
HOW YOLO SATISFIES IT · PRIMITIVE → REQUIREMENT
PRIMITIVE
REQUIREMENT SATISFIED
AUDIT CHAIN
FDA-EMA Good AI Practice · GxP audit trail
Every AI-influenced decision — drug candidate selection, trial design recommendation, safety signal classification, regulatory submission content — logged in a tamper-evident, hash-chained record. FDA inspectors, EMA reviewers, MHRA assessors can verify independently without trusting the sponsor.
IDENTITY REGISTRY
AI tool version traceability for regulatory submission
ERC-721 identity per AI tool version. Reproducibility requires knowing which exact version of which model generated which result. Permanent, third-party-verifiable version documentation across decade-long drug development lifecycles satisfies FDA version change documentation requirements.
DECISIONAL LOGGING
Per-decision capture across all tiers by research phase
Routine for discovery AI (molecular screening, target ID, literature synthesis). Consequential for clinical trial AI (patient selection, safety signal classification, protocol deviation flags). High-stakes for regulatory submission content, NDA/BLA decisions, and post-market recall classifications.
AUDIT CHAIN AND IDENTITY REGISTRY ARE LIVE ON BASE MAINNET TODAY.
PRICING · DECISIONAL LOGGING TIERS
ROUTINE
$0.0001 / event
Routine events
CONSEQUENTIAL
$0.01 / event
Consequential events
HIGH-STAKES
$0.10 / event
High-stakes events
VOLUME NOTE
Top-20 pharma realistic deployment: 500M routine × $0.0001 = $50K/year. 50M consequential × $0.01 = $500K/year. 100K high-stakes × $0.10 = $10K/year. Total: ~$560K/year baseline. Full deployment across all R&D + manufacturing + PV: $2M–$5M/year per top-20 pharma.
SCALE
$1M–$10M/year per top-20 pharma. $500K–$3M/year per mid-tier pharma. $2M–$15M/year per major CRO (IQVIA, Parexel, Syneos, ICON, PPD-Thermo, Charles River, Labcorp Drug Development) serving multiple sponsor clients. $250K–$2M/year per pharma AI vendor (Insitro, Recursion, Atomwise, Schrödinger, BenevolentAI, Owkin, Isomorphic Labs) as embedded audit layer.
FDA Warning Letter remediation: $5M–$50M per response + 6–24 month approval delay. Complete Response Letter after documentation gap: $50M–$500M in delayed launch. EU AI Act fine ceiling at 3%: Pfizer ~$59B revenue × 3% = $1.77B exposure. Manual GxP audit trail per FDA inspection per facility: $250K–$2M. GCP audit failure remediation: $1M–$10M + 12-month clinical hold. Single FDA inspection deficiency on AI traceability: trial placed on clinical hold.
ACTIVATION TRIGGER
August 2, 2026: EU AI Act high-risk effective for medical devices and IVDs. April 2, 2026: the FDA Purolea Cosmetics warning letter cited AI overreliance / lack of human oversight as a cGMP deficiency — AI decisions in regulated work now face enforcement scrutiny. January 14, 2026: FDA-EMA Joint Good AI Practice Principles published — sponsors with global submissions need parallel-jurisdiction documentation now.
MULTINATIONAL DEPLOYMENT
Global sponsors submitting to FDA + EMA + PMDA (Japan) + MHRA (UK) + TGA (Australia) face simultaneous GxP audit requirements across all five agencies. A single Yolo deployment produces the record-keeping evidence all five frameworks require — one record covering FDA 21 CFR Part 11, EMA Reflection Paper requirements, PMDA's AI-based SaMD guidance (PACMP, 2023), MHRA AI Strategy, and ICH Q7–Q11.
For Chief Medical Officer, Head of Quality Unit, Head of Regulatory Affairs, Chief Data Officer, Head of Pharmacovigilance, Head of GxP Compliance, Director of CSA/Computer System Validation, Director of AI/ML in Drug Development.